Bio-Thera will obtain an upfront payment of $21m and could earn up to $143.5m in development and commercial milestones.

New Delhi: Intas Pharmaceuticals has got approval from the Subject Expert Committee (SEC) functional under the Central Drug ...

Bio-Thera had entered into an exclusive licensing agreement with STADA Arzneimittel AG to commercialize BAT2506 in the European Union (UK), the United Kingdom (UK), Switzerland, and selected other ...

Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd. ("Intas Pharmaceuticals"), focused on the ...

Accord BioPharma Inc., the U.S. specialty division of Intas Pharmaceuticals Ltd., has reached an exclusive commercialization and license agreement with Bio-Thera Solutions for BAT2506, a biosimilar ...

Intas Pharma becomes most valuable privately held pharma company A PE deal values Intas at Rs 23,000 crore or USD 3.5 billion, making it the most valued pharma privately held company in India.

Learn about Intas Pharmaceuticals Ltd. in Ahmedabad, Gujarat.Find comprehensive contact details, including phone numbers and email addresses, and get directions to the location. If you own or are ...

Detailed price information for Sunshine Biopharma (SBFM-Q) from The Globe and Mail including charting and trades.

Among them, the cardiac, anti-diabetic, and gastrointestinal therapies saw high value growth of 10.9 per cent, 10.2 per cent, ...

Serplulimab is the world’s first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC; Serplulimab is the first and only anti-PD-1 mAb approved in th ...

Learn about Intas Pharmaceuticals in Dehradun, Uttarakhand.Find comprehensive contact details, including phone numbers and email addresses, and get directions to the location. If you own or are ...